I have been a part of the NIHR Group for the prevention and management of HIV-infection and non-communicable diseases in Africa at LSTM since 2017. Our current research focusses on evaluating strategies for the integrated delivery of HIV and non-communicable disease care as well as clinical studies on the prevention of diabetes.
I have co-ordinated 2 studies, one on integrating services for HIV-infection, diabetes and hypertension in Tanzania and Uganda, and a second large phase II randomised placebo-controlled trial on the use of metformin for the prevention of diabetes in HIV-infected persons in Tanzania.
I am a co-investigator on a randomised placebo-controlled double-blind phase III trial of metformin in HIV-infected persons with pre-diabetes in Tanzania. This is the largest trial of its kind in Africa. I was responsible for the design of the trial and am co-ordinating this and supporting implementation. I am also a co-investigator on a large cluster-randomised trial evaluating a novel approach of integrated clinical management of HIV-infection, diabetes, and hypertension in Tanzania and Uganda.
I also supervise UK public health trainees on placements at LSTM.
I trained in public health medicine in South Africa at a demographic surveillance site in KwaZulu-Natal. In the UK I have worked with NICE on clinical guideline development and in an NHS/Local Authority public health department.
Memberships and affiliations
Member of the Faculty of Public Health (UK)
Fellow of the College of Public Health Medicine (South Africa)
General Medical Council (UK)
EDCTP. Preventing and delaying the development of diabetes in Africa: a randomised placebo-controlled double-blind phase III trial of metformin in HIV-infected persons with pre-diabetes (2020-2024). £3.5m. Role: Co-investigator.
Horizon 2020. Integrating and decentralising diabetes and hypertension services in Africa (2019 – 2022). £4.0m. Role: Co-investigator
NIHR. Controlling chronic diseases in Africa: development and evaluation of an integrated community-based management for HIV-infection, diabetes and hypertension in Tanzania and Uganda. The INTE-COMM study (2020-2024). £4m. Role: Co-investigator.